MAL and ovarian serous adenocarcinoma: Highly expressed MAL gene in serous ovarian cancers from short-term survivors (<3 years) and treated with platinum-based therapy. MAL methylation status is a potential target for enhancing sensitivity to platinum-based drugs in epithelial ovarian cancer